Tobropt, eye drops 0.3% 5 ml

The antibiotic tobramycin in the preparation belongs to the broad-spectrum substances of the aminoglycoside group. It has bacteriostatic action (by blocking 30S ribosome subunit, disrupting protein synthesis of the bacteria).

The main activity of the drug is shown against coagulase-negative, coagulase-positive staphylococcal flora, penicillin-resistant strains (including Staphylococcusepidermidis, Staphylococcus aureus) and several types of streptococci (including group A beta-haemolytic strains, some non-haemolytic strains, Streptococcuspneumoniae). In addition, it acts on Pseudomonasaeruginosa, indole-positive and indole-negative Proteus species (including Proteusmirabilis, Proteusvulgaris), Haemophilusinfluenzae, Haemophilusaegyptius, Escherichiacoli, Klebsiellapneumoniae, Enterobacteraerogenes, Moraxellalacunata, Morganellamorganii, Neisseriaspp, Acinetobactercalcoaceticus. At the same time, some gentamicin-resistant strains retain high sensitivity to tobramycin. It is ineffective against group D streptococci.

Pharmacokinetics

It penetrates well through the blood-ophthalmic barrier. Systemic absorption when instilled into the conjunctival sac is insignificant. When injection into the conjunctival sac is detected at therapeutic concentrations in the corneal stroma, anterior chamber moisture, the vitreous body within 6 hours. Aminoglycosides are not metabolized, excreted by the kidneys.

Indications

Infections of the eye and its appendages:

Active ingredient

Composition

1 ml of eye drops contains:

the active ingredient:

Tobramycin – 3 mg

excipients:

boric acid,

sodium chloride,

sodium sulfate anhydrous,

tiloxapol, benzalkonium chloride,

1 M sodium hydroxide solution or 0.5 M sulfuric acid solution,

purified water.

How to take, the dosage

Topically.

1 drop every 4 hours; for acute infections, it can be repeated every 30 minutes or 1 hour.

In mild infections, the drug is instilled into the conjunctival sac of the affected eye (or eyes) every 4 hours in 1-2 drops.

In case of acute severe infectious process (endophthalmitis) the drug is instilled every 30-60 minutes; as the inflammation is reduced the frequency of the drug instillation is reduced.

Interaction

There may be increased systemic side effects (nephrotoxic, ototoxic effects, disorders of mineral metabolism and hematopoiesis) in case of simultaneous administration of the drug Tobropt with systemic antibiotics from the group of aminoglycosides.

Special Instructions

Tobropt is intended for topical use only.
It is necessary to close the bottle after each use.

Do not touch the pipette tip to the eye to maintain solution sterility.
Prolonged use of Tobropt, as with other antibiotics, may lead to increased growth of non-susceptible microorganisms (including fungi). It is recommended to do a culture after treatment is finished if the clinical result is not satisfactory.

Must not wear soft contact lenses during treatment. All types of hard contact lenses should be taken off while the drug is used. They can be put on 15 minutes after the drops are in.
Discontinue use if any allergic reactions develop.
Shake the bottle before use.

Impact on the ability to drive vehicles and operate special equipment
Use of Tobropt does not cause increased fatigue and visual impairment, so it does not affect the ability to drive vehicles and operate machinery. Patients who temporarily lose visual acuity after the application are not recommended to drive or operate complex equipment immediately after the application of the drug.

Contraindications

Side effects

When using the drug allergic reactions are possible:
in 15% of cases: burning, paresthesia, conjunctival itching;
in 1-5%: Hyperemia of the mucous membrane of the eye, sensation of a foreign body in the eye, lacrimation;
less than 1%: blepharitis, keratitis, edema of the eyelids, pain in the eye, chemosis, deposition of crystals, corneal ulceration.

Overdose

Symptoms: pitting keratitis, erythema, increased lacrimation, itching and swelling of the eyelid.

Treatment: symptomatic therapy is carried out.

Pregnancy use

The use of the drug during pregnancy and lactation (breastfeeding) is contraindicated.

Perinent use in children

It is contraindicated in children and adolescents under 18 years of age.

Similarities